Researchers Set Sights on Exosome-Based Early-Detection Blood Test for Pancreatic Cancer

A team of researchers from the University of California, San Diego (UCSD), published a study on March 23, 2018, evaluating a new strategy to analyze blood samples to search for clues indicating the presence of pancreatic cancer. The article, published in ACS Nano, is titled “Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood.” Patients whose pancreatic cancer is diagnosed early have a higher chance of long-term survival and increased access to treatment options, including surgery. However, there is currently no standard screening program or effective early detection strategy for pancreatic cancer. Researchers and organizations like the Pancreatic Cancer Action Network (PanCAN) are dedicated to identifying ways to effectively diagnose the disease earlier and improve patient outcomes. The new study from the UCSD team analyzed blood samples from people who had been diagnosed with pancreatic cancer, and compared them to blood from healthy individuals. Specifically, they isolated small particles, called exosomes, from the blood samples. Exosomes are tiny fluid-filled sacs that can contain protein and genetic material called RNA, which can provide information signifying the presence of disease. Previous work, such as a project conducted at MD Anderson Cancer Center (https://www.pancan.org/news/blood-test-could-potentially-diagnose-pancreatic-cancer-early/), has also focused on exosomes as a biomarker, or detectable and measurable substance that can indicate what’s happening inside a person’s body.
Login Or Register To Read Full Story